PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Data about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications,...

Full description

Bibliographic Details
Main Authors:	N. A. Shostak, A. A. Klimenko, N. A. Demidova, I. V. Novikov
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	pulmonary hypertension chronic thromboembolic pulmonary hypertension thromboembolism of pulmonary artery thromboendarterectomy bosentan prostacyclin analogues phosphodiesterase-5 inhibitors
Online Access:	https://www.rpcardio.com/jour/article/view/750

id	doaj-742081c33a9c4b3692950e06492be280
record_format	Article
spelling	doaj-742081c33a9c4b3692950e06492be2802021-09-03T13:15:19ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-017219920310.20996/1819-6446-2011-7-2-199-203749PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSIONN. A. Shostak0A. A. Klimenko1N. A. Demidova2I. V. Novikov3Russian State Medical UniversityRussian State Medical UniversityRussian State Medical UniversityRussian State Medical UniversityData about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications, results, limitations for CTPH surgical treatment are shown. Data of the currently completed clinical studies on bosentan, prostacyclin analogues and phosphodiesterase-5 inhibitors usage in CTPH are presented.https://www.rpcardio.com/jour/article/view/750pulmonary hypertensionchronic thromboembolic pulmonary hypertensionthromboembolism of pulmonary arterythromboendarterectomybosentanprostacyclin analoguesphosphodiesterase-5 inhibitors
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	N. A. Shostak A. A. Klimenko N. A. Demidova I. V. Novikov
spellingShingle	N. A. Shostak A. A. Klimenko N. A. Demidova I. V. Novikov PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Racionalʹnaâ Farmakoterapiâ v Kardiologii pulmonary hypertension chronic thromboembolic pulmonary hypertension thromboembolism of pulmonary artery thromboendarterectomy bosentan prostacyclin analogues phosphodiesterase-5 inhibitors
author_facet	N. A. Shostak A. A. Klimenko N. A. Demidova I. V. Novikov
author_sort	N. A. Shostak
title	PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
title_short	PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
title_full	PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
title_fullStr	PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
title_full_unstemmed	PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
title_sort	pathogenetic mechanisms and treatment principles of chronic thromboembolic pulmonary hypertension
publisher	Stolichnaya Izdatelskaya Kompaniya
series	Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn	1819-6446 2225-3653
publishDate	2016-01-01
description	Data about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications, results, limitations for CTPH surgical treatment are shown. Data of the currently completed clinical studies on bosentan, prostacyclin analogues and phosphodiesterase-5 inhibitors usage in CTPH are presented.
topic	pulmonary hypertension chronic thromboembolic pulmonary hypertension thromboembolism of pulmonary artery thromboendarterectomy bosentan prostacyclin analogues phosphodiesterase-5 inhibitors
url	https://www.rpcardio.com/jour/article/view/750
work_keys_str_mv	AT nashostak pathogeneticmechanismsandtreatmentprinciplesofchronicthromboembolicpulmonaryhypertension AT aaklimenko pathogeneticmechanismsandtreatmentprinciplesofchronicthromboembolicpulmonaryhypertension AT nademidova pathogeneticmechanismsandtreatmentprinciplesofchronicthromboembolicpulmonaryhypertension AT ivnovikov pathogeneticmechanismsandtreatmentprinciplesofchronicthromboembolicpulmonaryhypertension
_version_	1717816924163801088

PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Similar Items